Rapamycin and its analogs, everolimus significantly reduced cell growth of HCC and improved survival rate ASA404 DMXAA in the first instance by anti-angiogenic effect. A pilot study of 21 patients with advanced HCC has been suggested that sirolimus is a promising drug for the treatment of HCC and a randomized Phase I / II trials of the rapamycin analog RAD001 in advanced HCC patients currently.
ASA404 DMXAA western blot
One topic of big interest for the em signal transduction and molecular mechanisms of resistance of tumor cells to Herk Connected mmlichen cancer drugs. Obtained in this context A combination of rapamycin with ht Herk Mmlichen cytostatic antineoplastic activity of doxorubicin NVP-BEP800 and vinblastine, the t of the respective monotherapy with doxorubicin or vinblastine alone HCC. In addition to studies on the association of mTOR inhibitors with Herk Mmlichen chemotherapeutics two Phase I / II clinical trials are currently enrolling patients with advanced HCC, to determine the safety profile / toxicity T temsirolimus in combination with sorafenib. Taken together, led pr Clinical studies in vitro and in vivo and clinical studies to date show that mTOR inhibitors are promising drugs for the treatment of HCC, especially in combination with conventional drug Sen chemotherapy treatment.
Targeting the VEGF / VEGFR, the FGF / FGFR and PDGF / PDGFR WAY HCC is hypervascular tumor Haupts Chlich through the hepatic artery and secretion by HCC-cells, tumor-infiltrating inflammatory cells and hepatic stellate cells by factors fed such as VEGF, bFGF, angiopo tines, PDGF and other vascular lligkeiten sprouting of new vessel e of existing vascular s in the N he. VEGF is one of the most important factors stimulating angiogenesis, and is in most human tumors, confinement Regulated Lich HCC. In a recent systemic review and meta-analysis, the R VEGF as a prognostic Pr Established predictor of survival in treated patients with HCC. High concentrations of VEGF tissue predicts poor overall survival and disease-free of charge.
Similarly, high serum levels of VEGF predict poor overall survival and disease-free of charge. Therefore, the inhibition of angiogenesis is a potential therapeutic target in HCC, and many anti-angiogenic agents are currently being evaluated in clinical trials in HCC. Bevacizumab is a recombinant humanized monoclonal antibody Body against VEGF, which used either as monotherapy or in combination with other cytotoxic drugs or specifically in several clinical trials in patients already reached an advanced stage HCC, w While the other continues to recruit patients. Overall, the studies were that, although there is a proven bevacizumab is well tolerated, side effects associated with the administration, including normal bleeding, high blood pressure, proteinuria and thromboembolic events that warrant further evaluation. Several other RTK inhibitors targeting VEGF